# Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Source: https://onco.cc/trials/nct03970746/  
OnCo record `nct03970746` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by PDC*line Pharma SAS, active and no longer recruiting.

## Summary

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC is a phase 1/2 interventional study registered as NCT03970746 by PDC*line Pharma SAS, with 73 participants enrolled, started 2019-09-10 and due to reach its primary completion in 2024-07-18. Interventions recorded: PDC*lung01, Keytruda Injectable Product, Alimta Injectable Product. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03970746
- Phase: 1/2
- Setting: An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With Non-small-cell Lung Cancer (NSCLC)
- Sponsor: PDC*line Pharma SAS
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT03970746: https://clinicaltrials.gov/study/NCT03970746

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct03970746.json